[Targets and mechanisms of neutralizing monoclonal antibodies against Dengue virus].

Abstract

Dengue fever is a mosquito-borne disease prevalent in tropical and subtropical regions, with its prevalence expanding due to increased global travel. The dengue virus, the causative agent of dengue fever, often co-circulates in the form of four distinct serotypes. Cross-reactive antibodies generated during a primary infection pose a significant risk during secondary infections with different serotypes, and fully protective vaccines and antiviral drugs are yet to be developed. Over the past decade, advances in antibody technology have led to the isolation of numerous monoclonal antibodies against dengue virus, with their neutralizing epitopes elucidated through structure-based analyses. This review highlights the key epitopes associated with neutralizing antibodies against dengue virus and discusses their potential applications in vaccine design and therapeutic antibody development. This review helps systematically summarize the progress in dengue virus neutralizing antibody research, providing a theoretical foundation and technical guidance for the development of novel vaccines and antibody therapeutics.